Actionable news
All posts from Actionable news
Actionable news in TGTX: TG Therapeutics, Inc.,

TG Therapeutics, Inc. Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab)

Phase 2 study commenced to determine optimal dosing regimen in Relapsing MS patients

MS Program for TG-1101 targeted to enter Phase 3 in 2017

NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the opening of its Phase 2 clinical study of TG-1101 (ublituximab), the Company’s glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing remitting multiple sclerosis (RRMS), a chronic demyelinating disease of the central nervous system (CNS). This is the first company sponsored clinical trial evaluating the safety, tolerability, and efficacy of TG-1101 in autoimmune diseases. The Company is also supporting an investigator-sponsored study at John’s Hopkins University Medical Center that is currently enrolling patients with Neuromyelitis Optica (NMO), a related demyelinating disease similar to MS but of the optic nerve and spinal cord.

The study, entitled “A Placebo-Controlled Multi-Center Phase 2 Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis,” is being led by Edward Fox, MD, PhD, Director of the Multiple Sclerosis Clinic of Central Texas and Clinical Assistant Professor at the University of Texas Medical Branch in Round Rock, TX. The primary objective of the study is to determine the optimal dosing regimen for TG-1101 with a focus on accelerating infusion times. In addition to monitoring for safety and tolerability at each dosing cohort, B-cell depletion and established MS efficacy endpoints will also be evaluated.

Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer commented on the news, "We are excited to launch our first study in the treatment of patients with relapsing forms of MS, an area of significant unmet medical need. B-cell depletion therapy has recently proven to be highly effective in the treatment of both relapsing and progressive forms of MS. TG-1101 is a potent b-cell depleting agent; in our oncology studies TG-1101 has demonstrated an ability to cause rapid and profound B-cell depletion with a favorable safety profile. Additionally, early B-cell depletion...